CN102600114A - 香芹酚的应用 - Google Patents
香芹酚的应用 Download PDFInfo
- Publication number
- CN102600114A CN102600114A CN2012100323117A CN201210032311A CN102600114A CN 102600114 A CN102600114 A CN 102600114A CN 2012100323117 A CN2012100323117 A CN 2012100323117A CN 201210032311 A CN201210032311 A CN 201210032311A CN 102600114 A CN102600114 A CN 102600114A
- Authority
- CN
- China
- Prior art keywords
- carvacrol
- application
- mouse
- present
- ischemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- RECUKUPTGUEGMW-UHFFFAOYSA-N carvacrol Chemical compound CC(C)C1=CC=C(C)C(O)=C1 RECUKUPTGUEGMW-UHFFFAOYSA-N 0.000 title claims abstract description 44
- HHTWOMMSBMNRKP-UHFFFAOYSA-N carvacrol Natural products CC(=C)C1=CC=C(C)C(O)=C1 HHTWOMMSBMNRKP-UHFFFAOYSA-N 0.000 title claims abstract description 42
- WYXXLXHHWYNKJF-UHFFFAOYSA-N isocarvacrol Natural products CC(C)C1=CC=C(O)C(C)=C1 WYXXLXHHWYNKJF-UHFFFAOYSA-N 0.000 title claims abstract description 40
- 235000007746 carvacrol Nutrition 0.000 title claims abstract description 38
- 206010008118 cerebral infarction Diseases 0.000 claims abstract description 12
- 206010063837 Reperfusion injury Diseases 0.000 claims abstract description 9
- 201000006474 Brain Ischemia Diseases 0.000 claims abstract description 8
- 206010008120 Cerebral ischaemia Diseases 0.000 claims abstract description 7
- 239000000126 substance Substances 0.000 claims abstract 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 claims description 6
- 239000005844 Thymol Substances 0.000 claims description 3
- 229960000790 thymol Drugs 0.000 claims description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 2
- 229930007927 cymene Natural products 0.000 claims description 2
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 3
- 230000003188 neurobehavioral effect Effects 0.000 abstract description 3
- 210000003657 middle cerebral artery Anatomy 0.000 abstract description 2
- 208000012947 ischemia reperfusion injury Diseases 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 208000028867 ischemia Diseases 0.000 description 13
- 239000003814 drug Substances 0.000 description 12
- 201000008247 brain infarction Diseases 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000004043 dyeing Methods 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 230000000324 neuroprotective effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 1
- 206010070511 Hypoxic-ischaemic encephalopathy Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 210000000269 carotid artery external Anatomy 0.000 description 1
- 210000004004 carotid artery internal Anatomy 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 230000009449 neurobehavioral function Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
Images
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明公开了香芹酚的应用,所述香芹酚的分子式为C10H14O,其化学结构式为
Description
技术领域
本发明涉及一种香芹酚,具体的说,涉及一种香芹酚的应用。
背景技术
缺血性脑血管病是神经科常见病和多发病,具有发病率高、致残率高、死亡率高的“三高”特点,也是目前世界上致残致死最多的三大疾病之一。据世界卫生组织(WHO) 估计, 目前中国有500 万脑血管病患者, 每年约有160 万人死于脑血管病。随着我国人民生活水平的普遍提高和卫生保健系统的逐步完善, 人均寿命在不断延长, 以及我国人口老龄化的问题的出现, 脑血管病更加成为重要的公共卫生问题。因此对缺血性脑血管病人的治疗和护理费用已成为现代社会沉重的经济负担。脑缺血细胞死亡机制及神经损伤保护的靶点一直是基础实验和临床研究的重点。随着研究的深入,脑缺血损伤的病理生理过程逐渐被了解和认识。虽然研究人员针对脑血管病的这些损伤机制进行了积极的干预,然而除了早期应用组织型纤溶酶原激活剂溶栓治疗以外尚无有效的治疗手段。因此各国的研究人员都在积极寻找有效的临床神经保护药,以期能够减少中风病人的死亡率和致残率,减轻社会的负担。然而很多在动物实验中展示良好神经保护的药物,均未通过临床药物试验,其最重要的原因是该药物本身的毒副作用。所以我们在追求药物保护效果的同时,需要更加重视所用药物本身的性质,以期能找到安全可靠的保护缺血性脑损伤的药物。
发明内容
本发明针对目前使用于人类缺血性脑病的脑保护药物空白,本发明公开了一种天然的物质香芹酚在脑缺血再灌注损伤方面的应用。
香芹酚:
【英文名称】Carvacrol
【分子式】C10H14O;
【相对分子量或原子量】150.22
【密度】0.976(20/4°C)
【熔点(℃)】约0°C
【沸点(℃)】237-238
【闪点(℃)】105
【折射率】1.5229(20°C)
【毒性LD50(mg/kg)】家兔经口100
【性状】有麝香草酚气味的无色至淡黄色稠厚油状液体。
【溶解情况】易溶于醇和醚,微溶于水。能随水蒸汽挥发。
【用途】用于香料、食品添加剂、饲料添加剂、抗氧剂、卫生杀菌剂、驱虫剂、防腐剂、脱味剂、医药中间体。
本发明公开了香芹酚在在脑缺血再灌注损伤方面的应用,一方面其在动物的脑缺血再灌注损伤模型上展现了良好的脑保护作用,同时该药物具备着天然性及低毒性的特点。
优选的,所述香芹酚为2-羟基对异丙基甲苯、2-甲基-5-异丙基苯酚、2-对伞花酚、2-甲基-5-异丙基酚、异百里酚、2-羟基对伞花烃或对异丙基邻甲酚。
与现有技术相比,本发明具有以下优点:
所述香芹酚在小鼠大脑中动脉缺血再灌注损伤模型中,给实验鼠注入香芹酚明显了减小了脑梗死面积,提高了小鼠的神经行为学能力。
上述说明仅是本发明技术方案的概述,为了能够更清楚了解本发明的技术手段,并可依照说明书的内容予以实施,以下以本发明的较佳实施例并配合附图详细说明如后。
附图说明
此处所说明的附图用来提供对本发明的进一步理解,构成本申请的一部分,本发明的示意性实施例及其说明用于解释本发明,并不构成对本发明的不当限定。在附图中:
图1为香芹酚分子结构式。
图2为小鼠腹腔注入50mg/kg的香芹酚,缺血75分钟后再灌注24小时后,进行神经行为学评估的直方图。
图3为小鼠腹腔注入50mg/kg的香芹酚,缺血75分钟后再灌注24小时后,TTC染色后统计脑梗死面积的直方图。
图4为为小鼠腹腔注入不同比例的香芹酚,缺血75分钟后再灌注24小时后,TTC染色后统计脑梗死面积的直方图。
具体实施方式
下面将参考附图并结合实施例,来详细说明本发明。
一.小鼠大脑中动脉缺血模型:
1.老鼠
ICR 雄性,25-30g
2.线栓
6/0尼龙线,其末端包被硅胶
3.操作过程
给老鼠腹腔注射350mg/kg水合氯醛进行麻醉,应用头端涂适量硅胶的6—0单尼龙线自小鼠右侧颈外动脉向颈内动脉插入至大脑中动脉起始部,阻断其血流75分钟后拔出线栓实现再灌注。
二.神经行为学评分
小鼠在缺血后再灌注24小时后,进行神经行为功能评估:
0分为无神经功能缺失症状;
1分为提尾时右前肢内收,不能完全伸直;
2分为行走时向右侧旋转;
3分为向右侧倾倒;
4分为不能自己行走或昏迷。
评分采用双盲法,由未参与实验分组的人员完成。
三.操作过程
将实验老鼠分为假手术组(Sham),假手术+香芹酚组(CAR),缺血再灌注损伤组(I/R),缺血再灌注损伤+香芹酚组(I/R+CAR)(每组5只老鼠),在缺血前两小时,给老鼠腹腔注射50mg/kg的香芹酚,经过75分钟的缺血后再灌注24小时。先为存活的小鼠进行神经行为功能评估,然后处死后取脑,进行TTC染色,分析脑梗死的面积。
结合图进一步解释该药物的神经保护效果:
参见图1所示,为本发明的香芹酚分子结构式。
参见图2所示, 缺血前2小时给小鼠腹腔注入50mg/kg的CAR,缺血75分钟后再灌注24小时。进行神经行为学评估,I/R+CAR组的神经行为功能相对于I/R组有了明显的改善。这种改善具有统计学意义。
参见图3所示,缺血前2小时给小鼠腹腔注入50mg/kg的CAR,缺血75分钟后再灌注24小时。TTC染色后统计脑梗死面积。I/R+CAR组的脑梗死面积相对于I/R组明显减小。这种改变具有统计学意义。
参见图4所示,缺血前2小时给小鼠腹腔分别注入50mg/kg、25mg/kg、5mg/kg的CAR,缺血75分钟后再灌注24小时。TTC染色后统计脑梗死面积。I/R+CAR(50mg/kg)组和I/R+CAR(25mg/kg)组的脑梗死面积均小于I/R组。I/R+CAR(5mg/kg)组的梗死面积与I/R组的面积相当。说明该药物的神经保护作用有剂量依赖性。
以上所述仅为本发明的优选实施例而已,并不用于限制本发明,对于本领域的技术人员来说,本发明可以有各种更改和变化。凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (8)
2. 根据权利要求1所述的香芹酚的应用,其特征在于:所述香芹酚为2-羟基对异丙基甲苯。
3. 根据权利要求1所述的香芹酚的应用,其特征在于:所述香芹酚为2-甲基-5-异丙基苯酚。
4. 根据权利要求1所述的香芹酚的应用,其特征在于:所述香芹酚为2-对伞花酚。
5. 根据权利要求1所述的香芹酚的应用,其特征在于:所述香芹酚为2-甲基-5-异丙基酚。
6.根据权利要求1所述的香芹酚的应用,其特征在于:所述香芹酚为异百里酚。
7. 根据权利要求1所述的香芹酚的应用,其特征在于:所述香芹酚为2-羟基对伞花烃。
8.根据权利要求1所述的香芹酚的应用,其特征在于:所述香芹酚为对异丙基邻甲酚。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2012100323117A CN102600114A (zh) | 2012-02-14 | 2012-02-14 | 香芹酚的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2012100323117A CN102600114A (zh) | 2012-02-14 | 2012-02-14 | 香芹酚的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN102600114A true CN102600114A (zh) | 2012-07-25 |
Family
ID=46518143
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2012100323117A Pending CN102600114A (zh) | 2012-02-14 | 2012-02-14 | 香芹酚的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102600114A (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1350435A (zh) * | 1999-05-12 | 2002-05-22 | 阿克佐诺贝尔公司 | 一种用作杀菌剂的含有香芹酚和麝香草酚的组合物 |
-
2012
- 2012-02-14 CN CN2012100323117A patent/CN102600114A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1350435A (zh) * | 1999-05-12 | 2002-05-22 | 阿克佐诺贝尔公司 | 一种用作杀菌剂的含有香芹酚和麝香草酚的组合物 |
Non-Patent Citations (2)
Title |
---|
MEDIHA CANBEK, ET AL.: "Effects of carvacrol on defects of ischemia-reperfusion in the rat liver", 《PHYTOMEDICINE》, vol. 15, 31 December 2008 (2008-12-31), pages 447 - 452 * |
MUSTAFA UYANOGLU, ET AL.: "Preventing organ injury with carvacrol after renal ischemia/reperfusion", 《JOURNAL OF MEDICINAL PLANTS RESEARCH》, vol. 5, no. 1, 4 January 2011 (2011-01-04), pages 72 - 80 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105377371A (zh) | 创伤后应激障碍的治疗方法 | |
WO2015143928A1 (zh) | 治疗和预防妇女子宫颈癌的纳米银抗癌组合物及其制备方法和应用 | |
WO2011069184A1 (en) | Composition for treating skin lesions | |
CN102600114A (zh) | 香芹酚的应用 | |
Wolf et al. | Phase I Mp0112 wet AMD study: Results of a single escalating dose study with DARPin® MP0112 in wet AMD | |
Utku et al. | Intra-venous chlorpromazine with fluid treatment in status migrainosus | |
CN101766724B (zh) | 一种治疗跌打损伤、风湿骨痛的中药制剂及其制备方法 | |
CN105101969B (zh) | 包含硼酸、柠檬酸及锌的抗病毒剂组合物 | |
Grillo et al. | Lesions on tattooed skin: A case study | |
Sehn et al. | Adding polatuzumab vedotin (POLA) to bendamustine and rituximab (BR) treatment improves survival in patients with relapsed/refractory DLBCL: results of a phase 2 clinical trial | |
Béné et al. | Anaphylactic shock after misoprostol in voluntary termination of pregnancy–a case report | |
WO2022056736A1 (zh) | 左氧氟沙星或其药物可接受盐在制备抗脑缺血再灌注损伤的药物或保健品中的应用 | |
US10045952B2 (en) | Anti-Viral Compound and Composition | |
CN102657786B (zh) | 一种治疗躁狂症的饮剂 | |
Aggarwal et al. | Comparative study to test efficacy of topical permethrin and oral ivermectin in the management of scabies-a prospective randomized, single blinded controlled study. | |
Munshi et al. | Role of intralesioal Vitamin D in treatment of cutaneous warts | |
CN103495013B (zh) | 一种精神科护理上用于治疗焦虑症的药剂 | |
Bondariev | Optimization of prevention and treatment of cold trauma by means of metabolitotropic and anti-inflammatory action | |
CN100434080C (zh) | 一种治疗皮肤病的药物 | |
CN104586851A (zh) | Vernavosine在制备治疗中风药物中的应用 | |
Hoss | Fixed drug eruptions: case report | |
李妍 | Features of connected speech in patients with mild Alzheimer's disease | |
Jaime et al. | Placental abruption occurring soon after labor combined spinal-epidural analgesia | |
Jung et al. | Two cases of dermatitis patients during pregnancy | |
CN104415050A (zh) | 一种治疗病毒性疱疹的外用喷雾剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120725 |